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Leukopenia Management in Thymoglobulin Treated Renal Transplant Recipients
Lynsey A Biondi, MD, Michael J Moritz, MD and Janelle D Cyprich, Department of Surgery
Lehigh Valley Health Network, Allentown, Pennsylvania

Abstract:
Leukopenia is common following renal transplantation, though it is infrequently
reported and lacks well-defined management. We retrospectively reviewed 228
consecutive renal transplant recipients at a single center for leukopenia in the
first year following transplant. Leukopenic patients were evaluated for treatment
strategies, efficacy, and complications including CMV infection, rejection, graft
failure, and death. Leukopenia was observed in 43 of 228 (19%) transplants with
median onset and duration of 95 days. Ninety-three percent of patients received
®
treatment for leukopenia including Neupogen , dose reduction of mycophenolic
acid (MPA) or valganciclovir, and initiation of prednisone. Grade 2 neutropenia,
3
defined as ANC≤1000 cells/mm , had statistically significant increased incidence of
CMV (p<0.0001), defined as positive serum PCR, and rejection (p=0.013) compared
to non-leukopenic patients. MPA dose reductions >50% were associated with
higher rates of both CMV (60% v 42%) and rejection (60% v 33%). Conclusions: 1.
Leukopenic patients experience significantly increased CMV and rejection. 2. MPA
and valganciclovir dose reductions are associated with increased risk of rejection
®
and CMV. 3. Neupogen is an effective treatment for leukopenia.

Background:
While lymphocyte depleting induction immunosuppression agents are responsible for
much of the early post-transplant leukopenia, MPA and valganciclovir have also been
1-3
linked to a decrease in WBC count and ANC.

Methods:
This retrospective, single-center study included all patients undergoing kidney and/or
pancreas transplantation between January 2009 and May 2012. All recipients received
thymoglobulin 4-6mg/kg in 3-4 doses and maintenance MPA/tacrolimus. All leukopenic
episodes occurring between one month and one year post-transplant were analyzed.
Successful treatment of leukopenia was defined as a WBC count of greater than 3500
3
cells/mm for 30 days.

Rate of Rejection and CMV Associated
with MPA Dose Reduction

Results:
Leukopenic patients had significantly lower BMI (p=0.0152) than non-leukopenic
patients, but matched in age, gender, transplant type, and PRA. Interventions for
leukopenia were not standardized.
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Severely neutropenic patients had a statistically significant increased incidence of
CMV (p<0.0001) compared with non-leukopenic patients. Of the 20 leukopenic
patients who developed CMV, 10/20 (50%) developed CMV prior to leukopenia.
Compared with full dose valganciclovir, dose reduction was associated with a higher
rate of CMV (77% v 37%) p=0.021. Only 4 of 10 had dose reduction prior to the CMV
infection.
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Neutropenic patients also had a statistically significant increase in rejection
(p=0.013) compared with non-leukopenic patients. 11/17 (65%) leukopenic patients
experienced rejection after treatment of leukopenia.
While greater degrees of MPA dose reduction resulted in a shorter median duration of
leukopenia (110 v 74 days), greater MPA dose reductions were also associated with
higher rates of CMV and rejection (see graph).
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Of the 4 patients who received Neupogen without any medication dose reductions,
®
only 1 experienced rejection and CMV. Neupogen took the shortest amount of time to
recover WBC count (29 days) compared to prednisone (71 days), MPA dose reductions
(55 days), and valganciclovir dose reduction (35 days). It is difficult to attribute
improvement in leukopenia to one treatment given the multifactorial treatment
process.
®

Conclusions:
1. L eukopenic patients experience significantly increased CMV and rejection.
2. M
 PA and valganciclovir dose reductions are associated with an increased risk of
rejection and CMV.
®
3. N
 eupogen is an effective treatment for leukopenia.
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